Oncodesign Services is hosting a September webinar on optimizing in vitro candidates for radiopharmaceutical development.

Oncodesign Services supports biopharma and biotechnology teams navigating critical preclinical decisions as programs progress toward the clinic. At this stage, generating data alone is not enough; what matters is whether the evidence genuinely supports the next step forward. We are a preclinical contract research organization specializing in advanced development programs in targeted radiotherapy, oncology, immuno-oncology, and inflammation and autoimmune diseases. Our work is focused on the translational phase of drug development, where scientific rigor, careful study design, and clear interpretation are essential to support confident progression toward IND and clinical development. In targeted radiotherapy, we support programs from early candidate through IND-enabling studies, addressing challenges including radionuclide supply, biodistribution imaging, dosing strategy, and translational relevance. Our preclinical pharmacology work spans oncology, immuno-oncology, and immune-mediated inflammatory diseases, with studies designed around disease biology, proof of concept, and mechanism of action. Imaging approaches are integrated where appropriate to support longitudinal assessment of pharmacological effects, biodistribution, and target engagement. Model selection and development are tailored to the biological and translational questions driving each study. Our experience includes over 30 years in preclinical oncology, more than 20 years in imaging, and over 10 years in inflammatory disease and radiopharmaceutical development. Our facilities are AAALAC-accredited, reflecting internationally recognized standards for the humane and responsible use of animals in research.

Founded 1995